Evidence map›Paper›PMID 27690107›Full record

ReviewGenes2016

Modeling Fragile X Syndrome Using Human Pluripotent Stem Cells.

Hagar Mor-Shaked, Rachel Eiges

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Transcriptional Dysregulation and Impaired Neuronal Activity inInternational journal of molecular sciences · 2023
    Article
  3. Article
  4. iPSCs: A Preclinical Drug Research Tool for Neurological Disorders.International journal of molecular sciences · 2021
    Review
  5. Review
  6. Review
  7. iPSC modeling of rare pediatric disorders.Journal of neuroscience methods · 2020
    Review
  8. Review
  9. Review
  10. Reevaluation ofFrontiers in molecular neuroscience · 2018
    Review
  11. Of Men and Mice: Modeling the Fragile X Syndrome.Frontiers in molecular neuroscience · 2018
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hagar Mor-ShakedStem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical Center Affiliated with the Hebrew University School of Medicine, Jerusalem 91031, Israel. hagar.mor@mail.huji.ac.il.
Rachel EigesStem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical Center Affiliated with the Hebrew University School of Medicine, Jerusalem 91031, Israel. rachela@szmc.org.il.
Shaare Zedek Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragile X syndrome (FXS) is the most common heritable form of cognitive impairment. It results from a loss-of-function mutation by a CGG repeat expansion at the 5' untranslated region of the X-linked

Indexed as

disease modelingepigeneticsFMR1 geneFMRPfragile X syndromehuman embryonic stem cellsneurodevelopmentpatient-derived iPS cellsrepeat somatic instability

Identifiers

PMID27690107
PMCPMC5083916
OpenAlexW2525877752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.